01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – First volunteer dosed in intranasal COVID-19 vaccine clinical trial January 11, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the first volunteer has been dosed with the Codagenix Inc. (“Codagenix”) needle free, intranasal COVID-19 vaccine, COVI-VAC. Conducted by hVIVO, part of Open Orphan plc, the Phase I clinical trial of COVI-VAC is being carried out at their facility in the UK. COVI-VAC is a single-dose, intranasal, live…

Continue reading

Open Orphan #ORPH Chairman Cathal Friel talks to Ian King, Sky News about the Codagenix nasal Covid-19 vaccine phase I study December 15, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan #ORPH Chairman Cathal Friel talks to Ian King, Sky News about the Codagenix nasal Covid-19 vaccine phase I study, which has received regulatory approval. Tests start at the hVIVO Whitechapel facility in the new year. Cathal explains the simplicity, ease of application of the nasal application, and looks at the history of hVIVO’s East London facility.

Continue reading

Open Orphan #ORPH – MHRA approval for nasal COVID-19 vaccine clinical trial – Posted in: Uncategorized

First in human trials for vaccine candidate with the potential to confer long-term immunity Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services CRO which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials, announces the first in human (Phase I) study of Codagenix intranasal SARS-CoV-2 (COVID-19) vaccine candidate has received approval from the UK’s independent Medicines and Healthcare Products Regulatory Agency (MHRA). Further to the…

Continue reading

Open Orphan #ORPH – Interim Results for 6 months ended 30 June, will be operationally profitable in Q4 September 30, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan Plc, a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical studies is pleased to announce its interim results for the six months ended 30 June 2020. The interim results include the first six months of hVIVO group (“hVIVO”) following its acquisition by Open Orphan Plc on the 17 January 2020.   Operational Highlights: ·    Completed the acquisition of hVIVO…

Continue reading

The Times – Trial to infect British volunteers with modified coronavirus at hVIVO Quarantine Centre September 29, 2020 – Posted in: Open Orphan (ORPH)

Scientists are planning to infect British volunteers with a weakened, computer-designed form of the coronavirus, which researchers believe could work as a vaccine. The early-stage trial will take place in a special 24-bed quarantine clinic in Whitechapel, east London. The US biotech company behind it, Codagenix, is in talks with UK regulators and expects to begin before the end of the year. The vaccine consists of an enfeebled version of the coronavirus, designed using special…

Continue reading

Open Orphan #ORPH Awarded Contract From Codagenix Inc For COVID-19 Vaccine Trial July 27, 2020 – Posted in: Open Orphan (ORPH), Uncategorized

Tuesday 28th July, 2020 Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge clinical trials is pleased to announce a new contract with Codagenix Inc. (“Codagenix”) to conduct a first in human (Phase I) trial evaluating safety and immunogenicity of a single-dose, intranasal SARS-CoV-2 (COVID-19) vaccine candidate in 48 healthy young adult volunteers.   Highlights: First in human…

Continue reading